Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. Show more

Location: 225 Franklin Street, Boston, MA, 02110, United States | Website: https://ateapharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

314.1M

52 Wk Range

$2.46 - $4.14

Previous Close

$3.78

Open

$3.75

Volume

311,695

Day Range

$3.66 - $3.79

Enterprise Value

-115.9M

Cash

425.4M

Avg Qtr Burn

-31.55M

Insider Ownership

11.79%

Institutional Own.

66.86%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.